Friday December 1

Agenda Day 2

Panel discussion
08:40

Precision oncology needs data sharing: Integrating genomic and clinical data to advance patient care and understanding patient outcomes

  • Does decoding the genes of patients’ cancer help to accelerate the pace of discovery?
  • Is more sequencing, across large populations worthwhile?
  • How to combine all these data into one searchable pool?
  • How will this translate to better and more personalized vaccines or treatments for patients?
  • The paradigm of bringing multiple cancer centers together, connecting academics with industry and how to data share
  • The type of data sharing necessary to learn from the experience of patients that go through cancer immunotherapy
Prof Bali Pulendran
09:30

How to effectively manipulate the microbiome to improve efficacy of vaccines and immunotherapy

  • Understanding the microbiome and its interaction with the immune system
  • What evidence is there that one can change the other?
  • Potential opportunities and current challenges in harnessing this knowledge into better treatments
Dr Kara Bortone
10:00

Discussion: Driving innovation – Helping biotech’s to succeed from inception to expansion

  • What models can be used to support innovation?
  • What criteria do we look for in choosing biotech’s to work with?
  • How to be successful; programs and strategies to grow your company – how does this apply to vaccines and immunotherapy?
10:40

Morning Networking Break

11:40

Interactive Roundtables

Choose one of our roundtables for these interactive discussions with like-minded peers tackling the same challenges in:

Common logistics challenges that can delay clinical trials

Fuelling innovation through strategic investments in immunotherapy

In vivo evaluation of biomarkers and immune correlates of vaccine-induced protection

Microbiome biomarkers for cancer immunotherapy: promise and challenges

Overcoming clinical challenges that occur with combining different immuno-oncology approaches

Quality assurance and quality compliance in the development of personalised cancer vaccines

12:40

Networking Lunch & Poster Session

Vaccine Technology Platforms & Delivery

Clinical Advancements in Cancer and Autoimmune Diseases

Infectious Diseases
2:15

Developing vaccines for viral infections: Addressing HIV and Zika vaccine development

  • Results of Ph1b study for HIV vaccine
  • Moving into Ph11a proof of concept studies
  • Results of Zika pre-clinical studies
  • Preparing for Zika first in human trials
  • Has interest in Zika diminished? Impact on vaccine development
Immunotherapy
2:15

Development of novel, personalized neoantigen immunotherapies

  • Using real time next-generation sequencing and bioinformatics approaches to identify and catalogue neoepitopes for each patient
  • How algorithms have increased the accuracy of identifying neoepitopes from 1% - 40%
  • Manufacture and delivery of personalized cancer vaccines either alone or in combination with other therapeutics
Infectious Diseases
2:45

Development of a correlate of protection for a live oral cholera vaccine

  • Review of the immune response to cholera
  • Protective efficacy in a human challenge model
  • Establishment of a correlate for use in pre-licensure studies
  • Extension of this approach for post-approval studies
Immunotherapy
2:45

Optimizing the therapeutic benefit of PD-1 blockade and broadening the potential of immunotherapy

  • The past, present and future of anti-PD-1 therapies
  • Where are we currently with Keytruda monotherapy and biomarkers
  • Updates on our combination strategy and trials with Keytruda and other novel agents
Infectious Diseases
3:15

The use of next generation self-amplifying RNA platform systems for vaccine development

  • Why self-amplifying RNA systems?
  • Engineering beneficial attributes into RNA systems
  • In vitro analysis of engineered attributes
  • In vivo analysis of engineered attributes
  • Impact of engineered attributes on immunogenicity
Immunotherapy
3:15

Progress of chimeric antigen receptor (CAR) T-cells as an immuno-oncology treatment

  • Preliminary clinical outcomes of FIM clinical trial of CAR-GPC3 T cells in patients with advanced hepatocellular carcinoma
  • Bottlenecks in tech transfer for CAR-GPC3 T cells cross board manufacturing
  • Regulatory considerations when planning CAR-T clinical trials in China vs in US
3:30

Networking Break

Infectious Diseases
4:00

Electroporation mediated DNA immunization: Clinical progress and technology development

  • Review of clinical experience with electroporation based intradermal and intramuscular DNA vaccination
  • Development of electroporation device technology to support the development & deployment of novel DNA vaccine candidates
  • Adaptation of electroporation for delivery of DNA encoding monoclonal antibodies
Immunotherapy
4:00

Combining innate cellular therapy and adaptive immune therapy approaches for treatment of recurrent cancer

  • Rationale for combination of adenoviral vaccine with “superkine” IL-15 agonist
  • Partnering with NK cell therapy – mechanisms of action
  • Study design and initial safety
  • Early response data
Infectious Diseases
4:30

Immune profiling of T cell responses correlating with pertussis vaccine efficacy

  • Introduction of a whole cell pertussis vaccine in the 1950s led to dramatic reduction in morbidity
  • Whole pertussis inactivated vaccine was associated with significant side effects, replaced in 1997 with acellular version
  • Resurgence of pertussis in teenagers – age of people affected correlates with time when vaccine switched from whole cell vaccine to acellular vaccine occurred
  • Discussion of changes that have been identified in in immune profile between old vaccine and new
Immunotherapy
4:30

Beyond PD1s – Using a tumours composition to activate an immune response through STING pathway

  • Mode of action
  • Planned and ongoing clinical studies
  • Combination with vaccines
  • The importance of STING activation in priming patient’s tumours to respond to checkpoint inhibition
Infectious Diseases
5:00

Chair’s Closing Remarks & End of Congress

Immunotherapy
5:00

Chair’s Closing Remarks & End of Congress

last published: 22/Nov/17 13:05 GMT